Dear members of the press,
American Society of Clinical Oncology (ASCO)
Experts who lead the world’s cancer treatment gather to challenge the cutting edge of cancer treatment “ASCO Breakthrough” held for the first time in Japan
Date: August 3rd (Thursday) to August 5th (Saturday), 2023 Venue: Pacifico Yokohama (Kanagawa/Yokohama)
The American Society of Clinical Oncology (ASCO) will host ASCO Breakthrough, an international oncology conference in Asia, to spotlight novel and cutting-edge medical technologies that are transforming cancer care. .
The event will be organized and co-organized by ASCO, the Japanese Society of Oncology, the Japanese Society of Clinical Oncology, as well as several related societies in the Asia-Pacific region, and will be held face-to-face and virtually.
Bringing together oncology thought leaders, clinicians, medical technology pioneers, drug developers and pioneering researchers from around the world, the event will bring together CRISPR, gene editing and artificial intelligence (AI) to bring together science and enlightenment. , CAR-T and adoptive cell immunotherapy, novel therapeutics, and a wide range of other topics that are key to cancer care today. The first was held in Thailand in 2019, and this year it will be held in Yokohama.
The schedule of keynotes and sessions can be found on this website. https://conferences.asco.org/breakthrough/program
For general registration, please use the link below.
https://conferences.asco.org/breakthrough/welcome?cmpid=cr_ascoorg_brktsum_register_dsp_japanmed_all_btprospect_glob_050823___register_conv_image-logo-text_
[Image: https://prtimes.jp/i/122412/2/resize/d122412-2-585139ade18f409b6ad2-1.jpg&s3=122412-2-28997861c58102f7366cec770fbb301c-3900×2600.jpg ]
Overview of the event
■ Date and time
Thursday, August 3, 2023 to Saturday, August 5, 2023
■ Venue
Pacifico Yokohama (1-1-1 Minatomirai, Nishi-ku, Yokohama-shi, Kanagawa) *At this event, there will be plenty of online content such as live streaming sessions and Q&A sessions, making it easy for anyone who finds it difficult to come to the event in person to participate. ■ Main speakers
A wide variety of experts from all over the world will be on stage throughout the program.
・Hiroshi Mikitani: Chairman and CEO of Rakuten (Opening remarks and keynote speech)
・Maryellen Giger: Distinguished Professor of Radiology, Board of Medical Physics, University of Chicago (PhD, AN) (keynote speech) ・Chris Abbosh: Senior Director, Translational Medicine, AstraZeneca (MD, PhD) (Keynote Speech)
・Takayuki Yoshino: Director, Department of Gastroenterology, National Cancer Center Hospital East, Councilor of the Japanese Society of Clinical Oncology (Doctor of Medicine, PhD)
・Kohei Shitara: Director of Gastrointestinal Medicine, National Cancer Center Hospital East, Vice President of the Japanese Society of Clinical Oncology, International Chair of the Japanese Society of Clinical Oncology (Doctor of Medicine)
・Gilberto Lopes: University of Miami Sylvester Comprehensive Cancer Center (MD, FASCO)
・Melvin Lee Kiang Chua: Singapore National Cancer Center (MBBS, FRCR, PhD, FAMS) ■ Main executive committee members
・Yuichiro Toki: Director of the Japanese Society of Clinical Oncology (Doctor of Medicine, PhD)
・Tetsuya Mitsutomi: Specially Appointed Professor of Surgery, Kindai University School of Medicine (Doctor of Medicine)
・Lillian Siu: Princess Margaret Cancer Center, University of Toronto (MD, FASCO) ・Peter Yu: Hartford Healthcare (Ph.D., former ASCO President) ・Tony Mok: The Chinese University of Hong Kong (BMSc, MD, FRCP(C), FASCO) ・Rebecca Dent: Singapore National Cancer Center (MD)
■ Number of visitors
1000 people (planned)
program highlights
・Keynote speeches by global leaders in related fields.
・Interdisciplinary educational sessions dealing with the latest technologies, research and clinical practices, including sessions on precision care using artificial intelligence, CAR-T and adoptive cell therapy, novel therapeutic agents, and next-generation multi-omics technology.
• A special session focusing on solutions to the biggest obstacles to patient care in low- and medium-resource settings.
• Case-based sessions with key opinion leaders focusing on the latest research in specific disease sites.
・Daily “Abstract Sessions” present research content on the most important issues for participants in a short time.
・Daily “Poster Sessions” will feature presentations by experts in key research fields.
・Provide daily opportunities for interaction to encourage
collaboration with world-class clinicians and researchers who apply research results to practice.
・Simultaneous interpretation from English to Japanese will be provided in the general session of “ASCO Breakthrough”.
About the American Society of Clinical Oncology (ASCO)
Founded in 1964, the American Society of Clinical Oncology (ASCO(R)) operates under the principle that “knowledge beats cancer.” The Society, together with the Association for Clinical Oncology, represents more than 45,000 oncology professionals. Through research, education and the promotion of quality, equitable patient care, we work to defeat cancer, prevent or cure cancer, and achieve a world in which all survivors are healthy. In addition, ASCO’s foundation, Conquer Cancer, supports ASCO by funding groundbreaking research and education in all aspects of cancer.
For more information about ASCO, please visit: www.ASCO.org
For patient education resources, please visit: www.Cancer.Net Facebook: https://www.facebook.com/ASCOCancer
Twitter: https://twitter.com/ASCO
LinkedIn: https://www.linkedin.com/company/american-society-of-clinical-oncology Instagram: https://www.instagram.com/ascocancer/
YouTube: https://www.youtube.com/user/ASCOcancer
About the Japanese Society of Clinical Oncology (JSCO)
The Japanese Society of Clinical Oncology (JSCO) is the largest clinical oncology society in Japan with over 17,000 members. Its purpose is to cover a wide range of clinical fields and occupations, and to provide a platform for cross-sectional medical care, research, and human resource development that meets the needs of the times. JSCO conducts research and educational activities from a standpoint that transcends academic and specific fields, and continues to actively tackle issues that are difficult for specialist societies that cover limited fields to deal with.
About the Japanese Society of Medical Oncology (JSMO)
The Japanese Society of Medical Oncology (JSMO) was established with the aim of contributing to the extension of survival and the improvement of the quality of life (QOL) of cancer patients, and is engaged in the following activities: 1) To promote the spread of cancer care among medical professionals and medical institutions, and (2) To improve the level of cancer care through education of medical professionals, including the continuous training of JSMO-certified medical oncologists. (3) Contribute to the development of new cancer treatment by supporting the academic activities of its members; (4) Enlighten citizens by providing accurate information on cancer treatment and cancer research. (5) Contribute to both cancer treatment and research in the international community through collaboration with overseas related academic societies.
Details about this release:
https://prtimes.jp/main/html/rd/p/000000002.000122412.html
MAIL:cr@prtimes.co.jp
Copyright (c) PR TIMES Corporation.